期刊
MOLECULES
卷 27, 期 21, 页码 -出版社
MDPI
DOI: 10.3390/molecules27217624
关键词
drug discovery; computational chemistry; molecular design; pharmaceutical industry; epistemiology
The underperformance of the pharmaceutical discovery process is mainly due to profit-driven rather than society-driven search for new pharmaceutical products. Insufficient funding and lack of systematic approaches result in underuse of innovative methods and limitations of dominant methodologies. To fully capitalize on the potential of pharmaceutical intervention, a fundamental shift in attitude towards reliance on computational approaches and moving away from commercial imperatives is essential.
Faced with new and as yet unmet medical need, the stark underperformance of the pharmaceutical discovery process is well described if not perfectly understood. Driven primarily by profit rather than societal need, the search for new pharmaceutical products-small molecule drugs, biologicals, and vaccines-is neither properly funded nor sufficiently systematic. Many innovative approaches remain significantly underused and severely underappreciated, while dominant methodologies are replete with problems and limitations. Design is a component of drug discovery that is much discussed but seldom realised. In and of itself, technical innovation alone is unlikely to fulfil all the possibilities of drug discovery if the necessary underlying infrastructure remains unaltered. A fundamental revision in attitudes, with greater reliance on design powered by computational approaches, as well as a move away from the commercial imperative, is thus essential to capitalise fully on the potential of pharmaceutical intervention in healthcare.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据